Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension.

MRAP2 功能丧失突变是高血糖和高血压伴过度摄食性肥胖的致病因素

阅读:8
作者:Baron Morgane, Maillet Julie, Huyvaert Marlène, Dechaume Aurélie, Boutry Raphaël, Loiselle Hélène, Durand Emmanuelle, Toussaint Bénédicte, Vaillant Emmanuel, Philippe Julien, Thomas Jérémy, Ghulam Amjad, Franc Sylvia, Charpentier Guillaume, Borys Jean-Michel, Lévy-Marchal Claire, Tauber Maïthé, Scharfmann Raphaël, Weill Jacques, Aubert Cécile, Kerr-Conte Julie, Pattou François, Roussel Ronan, Balkau Beverley, Marre Michel, Boissel Mathilde, Derhourhi Mehdi, Gaget Stefan, Canouil Mickaël, Froguel Philippe, Bonnefond Amélie
The G-protein-coupled receptor accessory protein MRAP2 is implicated in energy control in rodents, notably via the melanocortin-4 receptor(1). Although some MRAP2 mutations have been described in people with obesity(1-3), their functional consequences on adiposity remain elusive. Using large-scale sequencing of MRAP2 in 9,418 people, we identified 23 rare heterozygous variants associated with increased obesity risk in both adults and children. Functional assessment of each variant shows that loss-of-function MRAP2 variants are pathogenic for monogenic hyperphagic obesity, hyperglycemia and hypertension. This contrasts with other monogenic forms of obesity characterized by excessive hunger, including melanocortin-4 receptor deficiency, that present with low blood pressure and normal glucose tolerance(4). The pleiotropic metabolic effect of loss-of-function mutations in MRAP2 might be due to the failure of different MRAP2-regulated G-protein-coupled receptors in various tissues including pancreatic islets.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。